Candel Therapeutics Inc
NASDAQ:CADL

Watchlist Manager
Candel Therapeutics Inc Logo
Candel Therapeutics Inc
NASDAQ:CADL
Watchlist
Price: 5.94 USD 6.64%
Market Cap: 326.1m USD

EV/EBITDA
Enterprise Value to EBITDA

-6
Current
-4
Median
6.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-6
=
Enterprise Value
240.1m USD
/
EBITDA
-39.7m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
Candel Therapeutics Inc
NASDAQ:CADL
Average EV/EBITDA: 40.1
Negative Multiple: -6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 560.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.7
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18.4
11%
1.7
US
Gilead Sciences Inc
NASDAQ:GILD
13
7%
1.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.3
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -580.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.2
11%
1.6
AU
CSL Ltd
ASX:CSL
12.7
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
161.3
N/A N/A
NL
argenx SE
XBRU:ARGX
58.5
807%
0.1

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
hidden
2-Years Forward
EV/EBITDA
hidden
3-Years Forward
EV/EBITDA
hidden